Selection of chemotherapy for patients with advanced non-small cell lung cancer

Cleveland Clinic Journal of Medicine

Volumn 79, Issue ELECTRONICSUPPL.1, 2012, Pages 46-50

  Pennell, Nathan A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866771210     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2.10     Document Type: Article

References (20)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
2. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2450.
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
5. Peterson P, Park K, Fossella F, Gatzmeier U, John W, Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [12th World Congress on Lung Cancer abstract P2-328]. J Thorac Oncol 2007; 2(suppl 4):S851.
6. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14:253-263.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
9. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced nonsmall cell lung cancer (NSCLC) [ASCO abstract CRA8000]. J Clin Oncol 2009; 27(suppl).
10. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284-3289.
11. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the PointBreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/ bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009; 10:252-256.
12. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010; 28(suppl):abstr 7500.
13. Socinski MA, Bondarenko IN, Karaseva NA, et al. Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer [ASCO abstract 7551]. J Clin Oncol 2011; 29(suppl).
14. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
15. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2008; 27:591-598.
16. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-529.
17. Miller VA, O'Connor P, Soh C, Kabbinavar F; ATLAS investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract LBA8002]. J Clin Oncol 2009; 27(suppl).
18. Perol M, Zalcman G, Monnet I, et al. Final results from the IFCTGFPC 0502 phase III study: Maintenance therapy in advanced NSCLC with either gemcitabine (G) or erlotinib (E) versus observation (O) after cisplatin-gemcitabine induction chemotherapy (CT), with a predefined second-line treatment [ESMO abstract 370PD]. Ann Oncol 2010; 21(suppl 8):viii124.
19. Perol M, Chouaid C, Milleron J, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined secondline treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study [ASCO abstract 7507]. J Clin Oncol 2010; 28:(suppl).
20. Barlesi F, de Castro J, Dvornichencko V, et al. AVAPERL (MO22089): Final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer randomized to continuation maintenance with bevacizumab (bev) or bev + pemetrexed (pem) after first-line bev-cisplatin-pem treatment. Paper presented at: The European Multidiscipinary Cancer Congress; September 24, 2011; Stockholm, Sweden.